Radiation damage of salivary gland in patients with differentiated thyroid cancer
Conditions
Interventions
control group:No special treatment required
experimental group:Starting from 2 hours after iodine treatment, VitC tablets were included, 100mg / time, 6 times / day, for one week
Sponsors
Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with differentiated thyroid cancer were diagnosed with papillary thyroid carcinoma, follicular thyroid carcinoma or mixed thyroid carcinoma. 2) All patients were treated with 131I thyroidectomy after discontinuation of thyroxine sodium and low iodine diet for 3-4 weeks. 3) Patients who can cooperate with the test. 4)All patients voluntarily participate and sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Severe heart, liver and kidney dysfunction, as well as diabetes, hypertension and hypotension. 2) The patient had previous history of salivary gland disease, head and neck radiation therapy, or autoimmune disease. 3) The patient had taken drugs that affected salivary secretion, such as anticholinergics, antidepressants, or ß-adrenergic blockers, during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UR;MS;SUVmax; | — |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic dose of 131I; | — |
Countries
China
Contacts
Public ContactBing Cheng
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed